Aria CV Begins ASPIRE PH EFS of Second-Generation Pulmonary Hypertension System

February 27, 2024—Aria CV, Inc. announced that the first patient was implanted with the second-generation Aria CV pulmonary hypertension system as part of the ASPIRE PH clinical trial. ASPIRE PH is a feasibility study assessing the initial safety, tolerability, and efficacy of the Aria system under the FDA’s Early Feasibility Study (EFS) program.

The implantation procedure was performed by Ashwin Ravichandran, MD, and Scott Hittinger, MD, at Ascension St. Vincent Cardiovascular Research Institute in Indianapolis, Indiana.

According to the company, the Aria CV system is an implantable gas-filled balloon that is introduced percutaneously and functions in the main pulmonary artery to alleviate the excessive workload on the right heart that results in right heart failure. The device is intended to restore the benefits of a healthy pulmonary artery by reducing cardiac workload and enhancing blood flow through the lungs.

“We are proud to have performed the first implant of this novel device, as it offers an alternative treatment for patients who remain significantly impacted by right heart dysfunction related to pulmonary hypertension, which has limited approved therapy options,” commented Dr. Ravichandran in Aria CV’s press release.